Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...
A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...
In a Monday matchup at Mount Abraham Union High School between two Division II field hockey teams that have played hard this fall, but could use more positive results, the host Eagles used a fast ...
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...
Investor's Business Daily on MSN19h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback